Clinical trials
Phase 3 trials in Ethiopia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2018 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 4 |
| Not yet recruiting | 3 |
| Active, not recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Drugs for Neglected Diseases | 3 |
| Institute of Tropical Medicine, Belgium | 3 |
| Menzies School of Health Research | 3 |
| Population Health Research Institute | 2 |
| GlaxoSmithKline | 1 |
| IUATLD, Inc | 1 |
| Janssen Infectious Diseases BVBA | 1 |
| Janssen Research & Development, LLC | 1 |
| Jimma University | 1 |
| London School of Hygiene and Tropical Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leishmaniasis, Visceral | 4 |
| Malaria, Vivax | 4 |
| Acquired Immunodeficiency Syndrome | 2 |
| Leishmaniasis, Cutaneous | 2 |
| Malaria | 2 |
| Malaria, Falciparum | 2 |
| Recurrence | 2 |
| Tuberculosis, Multidrug-Resistant | 2 |
| Atrial Fibrillation | 1 |
| Bipolar Disorder | 1 |
Trials
Showing 76 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.